The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Abiraterone plus prednisone alone or with dasatinib in chemotherapy-naive metastatic castrate-resistant prostate cancer (mCRPC).
Tanya B. Dorff
Consultant or Advisory Role - Janssen
Research Funding - Bristol-Myers Squibb
Susan G. Groshen
No relevant relationships to disclose
David I. Quinn
Consultant or Advisory Role - Algeta; Amgen; Astellas Pharma; AVEO; Bayer; Dendreon; Fresenius Biotech; Genentech; Janssen; Medivation; Novartis; Prometheus
Honoraria - Algeta; Amgen; Astellas Pharma; AVEO; Bayer; Dendreon; Fresenius Biotech; Genentech; Janssen; Medivation; Novartis; Pfizer; Prometheus
Research Funding - Millennium; Sanofi
Expert Testimony - Medivation; Teva
Amir Goldkorn
Research Funding - Janssen Biotech
Cynthia L. Martel
No relevant relationships to disclose
Jacek K. Pinski
Honoraria - Janssen Pharmaceutical
Peter Kuhn
No relevant relationships to disclose
Mitchell E. Gross
No relevant relationships to disclose